LBF20107PG08: Difference between revisions
No edit summary |
No edit summary |
||
| (19 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
| Line 4: | Line 6: | ||
|LipidBank=XPR1731 | |LipidBank=XPR1731 | ||
|LipidMaps=LMFA03010049 | |LipidMaps=LMFA03010049 | ||
|SysName= 9alpha,15S- | |SysName=(9alpha,15S) -Dihydroxy-11-oxo-prost-trans-13-en-1-oic acid | ||
|Common Name=&&Prostaglandin | |Common Name=&&Prostaglandin D_1&&(9alpha,15S) -Dihydroxy-11-oxo-prost-13(E)-en-1-oic acid&& | ||
|Source= | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity=Prostaglandin D1 inhibits ADP-induced human platelet aggregation effect (IC50 value of 320 ng/ml). [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]Prostaglandin D1 inhibits the increase in vascular permeability in rat skin produced by prostaglandin E1, E2 and D2.[[Reference:Flower_RJ:Kingston_WP:,Br. J. Pharmacol.,1975,55,239P|{{RelationTable/GetFirstAuthor|Reference:Flower_RJ:Kingston_WP:,Br. J. Pharmacol.,1975,55,239P}}]] PGD1 is equal in activity to PGF1 alpha in causing constriction of central and peripheral airways of the dog.[[Reference:Spannhake_EW:Levin_JL:Hyman_AL:Kadowitz_PJ:,Prostaglandins Leukot. Essent. Fatty Acids,1983,10,123|{{RelationTable/GetFirstAuthor|Reference:Spannhake_EW:Levin_JL:Hyman_AL:Kadowitz_PJ:,Prostaglandins Leukot. Essent. Fatty Acids,1983,10,123}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | |||
Latest revision as of 08:04, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1731 |
| LipidMaps | LMFA03010049 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20107PG08 |
| Prostaglandin D1 | |
|---|---|
| |
| Structural Information | |
| (9α,15S) -Dihydroxy-11-oxo-prost-trans-13-en-1-oic acid | |
| |
| Formula | C20H32O4 |
| Exact Mass | 336.23005951199997 |
| Average Mass | 336.46567999999996 |
| SMILES | C(CC[C@H](O)C=C[C@H]([C@H]1CCCCCCC(O)=O)C=CC(=O)1)CC |
| Physicochemical Information | |
| Prostaglandin D1 inhibits ADP-induced human platelet aggregation effect (IC50 value of 320 ng/ml). Bundy_GL et al.Prostaglandin D1 inhibits the increase in vascular permeability in rat skin produced by prostaglandin E1, E2 and D2. Flower_RJ et al. PGD1 is equal in activity to PGF1 alpha in causing constriction of central and peripheral airways of the dog. Spannhake_EW et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
